Brought to you by 
Pfizer pays $5.2bn in cash for Anacor
08 Sep 2020
Executive Summary
Pfizer Inc. is paying $5.2bn--$99.25 per share, a 57% premium--in cash to acquire Anacor Pharmaceuticals Inc. The purchase price is net of cash and assumes the conversion of Anacor’s outstanding convertible debt.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer pays $5.2bn in cash for Anacor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice